A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects
Status:
Completed
Trial end date:
2021-07-13
Target enrollment:
Participant gender:
Summary
The purpose of the first-in-human (FIH) study is to obtain safety, tolerability, and
pharmacokinetic information on SAR442501 in a healthy adult volunteer population using an
integrated single ascending dose (SAD)-multiple ascending dose (MAD) parallel cohort study
design.